Data from clinical trials of Provenge appears to have been analyzed differently by researchers...

|By:, SA News Editor

Data from clinical trials of Provenge appears to have been analyzed differently by researchers than how Dendreon (DNDN +0.2%) told the FDA it would be. DNDN had originally said the data would be analyzed by age, using a cut-point of 65, but when the report was published its stated age was 71. The company says the discrepancy is immaterial and that Provenge is safe and effective. The FDA also stands by its decision to approve the treatment.